Daily Rounds

🧠 - Heidelberg scientists have identified a protein pairing that acts as a molecular "death switch" in Alzheimer's disease, and a new compound can break it apart, protecting neurons even as it reduces amyloid. 🧬 - The first-ever human trial of partial epigenetic reprogramming is now enrolling, with Life Biosciences testing ER-100 in patients with retinal degeneration in a trial that could redefine what it means to treat aging at the cellular level. 💊 - GLP-1 receptor agonists do not cause disproportionate muscle loss, and new data shows they actually increase mitochondrial proteins in skeletal muscle, suggesting metabolic benefits that go well beyond weight reduction. 🦠 - Gut bacteria are actively injecting proteins into human intestinal cells via molecular syringes, and this mechanism appears more prevalent in people with Crohn's disease, pointing to a new pathway for understanding and treating chronic gut inflammation. ⌚ - ARPA-H's new Delphi program is funding wearable biosensors that can continuously track cytokines and hormones in real time, a potential leap from tracking symptoms to detecting the earliest biological signals of disease and aging.

❤️ New ACC/AHA guidelines recommend cardiovascular screening starting at age nine and statin consideration at 30, with evolocumab cutting first heart attacks by 31 percent in diabetes patients. 🤖 Eli Lilly's $2.75 billion deal with Insilico Medicine marks the largest AI drug discovery partnership ever, as over 173 AI-discovered drugs advance through clinical trials toward the first potential FDA approval. 🦠 A gut bacteria compound called Bac429 doubled cancer immunotherapy response in resistant lung tumors and is now being prepared for human testing. 😴 A study of nearly 39,000 adults proved that combining morning sunlight, time-restricted eating, Zone 2 exercise, and five minutes of breathwork significantly improves sleep, fitness, and nervous system resilience. ⛰️ Multi-biomarker wearables combining glucose, heart, temperature, and activity sensing are launching in 2026, while the first needle-free CGM has received FDA clearance.

🧬 Epigenetic reprogramming has entered human trials — Life Biosciences is now enrolling patients in the first FDA-cleared age-reversal study. 🧠 Two major Alzheimer's breakthroughs this week — a newly identified "death switch" molecule and CAR-astrocyte plaque cleaners. 🤖 AI co-scientists are validating drug discoveries in real time — Google's system confirmed AML drug candidates; NVIDIA + Lilly committed $1B to the space. 🦠 A single gut bacteria molecule doubled cancer immunotherapy response — Bac429 is moving toward human drug development. 😴 Sleep is about daytime function, not just nighttime hours — a new clinical framework is changing how insomnia is measured and treated.

Your daily briefing on the latest breakthroughs in longevity science, health technology, and lifestyle optimization — curated from the world's top research institutions.

Your daily brief on the latest longevity science, health technology, and lifestyle research — covering cellular health, AI in medicine, cardiovascular breakthroughs, sleep science, and more.